Beta blocker therapy and prevention of apoptosis

  • Andreas V. Sigel
  • Heribert Schunkert
Part of the Basic Science for the Cardiologist book series (BASC, volume 5)


Chronic congestive heart failure, initiated by ischemic or hypertensive damage of the myocardium, can continue to worsen over months or years, despite the absence of clinically apparent acute events. Electron microscopic studies using myocardial specimen obtained from failing human hearts (1) and hearts of dogs with experimental heart failure (2) have clearly established the existence of cardiomyocyte apoptosis. Thus, it has been hypothesized that progressive cell loss by myocyte apoptosis may accelerate the natural course of congestive heart failure. Activation of neurohormonal mechanisms including the beta adrenergic system has been suggested to induce myocyte apoptosis and, thus, to promote the course of heart failure.


Congestive Heart Failure Cardiac Myocytes Renin Angiotensin System Sympathetic Nervous System Activity Chronic Congestive Heart Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P. Apoptosis in the failing human heart. N Engl J Med 1997; 336: 1131–1141.PubMedCrossRefGoogle Scholar
  2. 2.
    Sabbah HN, Sharov VG. Apoptosis in heart failure. Prog Cardiovasc Dis 1998; 40: 549–562.PubMedCrossRefGoogle Scholar
  3. 3.
    Feuerstein G, Yue TL, Ma X, Ruffolo RR. Novel mechanism in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 1998; 48(Suppl 1): 17–24.CrossRefGoogle Scholar
  4. 4.
    Ruffolol RR, Feuerstein GZ. Carvedilol: preclinical profile and mechanisms of action in preventing the progression of congestive heart failure. Eur Heart J 1998; 19(Suppl B): 19–24.Google Scholar
  5. 5.
    Ruffolo RR, Feuerstein GZ, Ohlstein EH. Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure. Am J Hypertension 1998; 11: 9–14.CrossRefGoogle Scholar
  6. 6.
    Feuerstein GZ, Bril A, Ruffolo RR. Protective effects of carvedilol in the myocardium. Am J Cardiol 1997; 80: 41L–45L.PubMedCrossRefGoogle Scholar
  7. 7.
    Kukin MK, Kaiman J, Charney RH, Levey DK, Buchholz-Varley C, Ocampo ON, Eng C. Prospective, randomized comparison of effect of long-term treatment with metropolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999; 99: 2645–2651.PubMedGoogle Scholar
  8. 8.
    Katz AM. Cardiomyopathy of overload: a major determinant of prognosis in congestive heart failure. N Engl J Med 1990; 322: 100–109.PubMedGoogle Scholar
  9. 9.
    Jennings GL, Esler MD. Circulatory regulation at rest and exercise and the functional assessment of patients with congestive heart failure. Circulation 1990; 81(Suppl II): 5–11.Google Scholar
  10. 10.
    Hasking GJ, Esler MD, Jennings GL. Norepinephrine spillover to plasma in patients with congestive heart failure, Evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986; 73: 615–625.PubMedGoogle Scholar
  11. 11.
    Rose CP, Burgess JH, Cousineau D. Tracer norepinephrine kinetics in coronary circulation of patients with heart failure secondary to chronic pressure and volume overload. J Clin Invest 1985; 76:1740–1751.PubMedGoogle Scholar
  12. 12.
    Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998; 98: 1329–1334.PubMedGoogle Scholar
  13. 13.
    Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980; 44: 117–133.PubMedGoogle Scholar
  14. 14.
    Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, for the metropolol in dilated cardiomyopathy (MDC) trial study group: beneficial effects of metropolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441–1446.PubMedCrossRefGoogle Scholar
  15. 15.
    Ruffolo RR, Bril A, Feuerstein GZ. Cardioprotective potential of carvedilol. Cardiology 1993; 82(Suppl 3): 24–28.PubMedGoogle Scholar
  16. 16.
    Yue TL, Ma XL, Wang X, Romanic AM, Liu GL, Louden C, Gu JL, Kumar S, Poste G, Ruffolo RR Jr, Feuerstein GZ. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res 1998; 82: 166–174.PubMedGoogle Scholar
  17. 17.
    CIBIS-II investigators and committees. The cardiac insufficiency bisoprolol study II (C1BIS II): a randomised trial. Lancet 1999; 353:9–13.CrossRefGoogle Scholar
  18. 18.
    Sigel AV, Romanic AM, Peng CF, Schunkert H, Feuerstein G, Riegger GAJ and Yue TL. Hypoxia and reoxygenation related injuries in cardiac myocytes are enhanced by programmed cell death: Differential protective effects of beta-adrenergic receptor blockers. Circulation 1998; 19: 742A.Google Scholar
  19. 19.
    Design of the beta-blocker evaluation survival trial (BEST). The BEST steering committee. Am J Cardiol 1995: 1220–1223.Google Scholar
  20. 20.
    CIBIS investigators and Committees: A randomized trial of β-blockade in heart failure. The cardiac insufficiency bisoprolol study (CIBIS). Circulation 1994; 1765–1773.Google Scholar
  21. 21.
    Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94: 2817–2825.PubMedGoogle Scholar
  22. 22.
    Australian-New Zealand Heart Failure Research Colloborative Group: Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375–380.CrossRefGoogle Scholar
  23. 23.
    Rationale, design, and organization of the metoprolol CR/XL randomized intervention trial in heart failure (MERIT-HF). The international steering committee. Am J Cardiol 1997; 80: 54J–58J.CrossRefGoogle Scholar
  24. 24.
    Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shudterman N, for the MOCHA investigators: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807–2816.PubMedGoogle Scholar
  25. 26.
    Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022–1036.PubMedGoogle Scholar
  26. 27.
    Luchner A, Burnett JC, Jougasaki M, Hense HW, Riegger GA, Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 1998; 32: 1839–1844.PubMedCrossRefGoogle Scholar
  27. 28.
    Holmer SR, Hense HW, Danser AH, Mayer B, Riegger GA, Schunkert H. Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics. Heart 1998; 80: 45–48.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2000

Authors and Affiliations

  • Andreas V. Sigel
    • 1
  • Heribert Schunkert
    • 1
  1. 1.Universität RegensburgRegensburgGermany

Personalised recommendations